Skip to main navigation Skip to search Skip to main content

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

  • IMblaze370 Investigators
  • University of Texas MD Anderson Cancer Center
  • University of Ulsan
  • Sarah Cannon Research Institute
  • Vall d'Hebron Institute of Oncology
  • Austin Health
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • Pisa University Hospital
  • City of Hope National Med Center
  • The University of Chicago
  • Memorial Sloan-Kettering Cancer Center
  • University Eye Clinic
  • Genentech, Inc
  • University of Campania Luigi Vanvitelli

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science